Eton Pharmaceuticals (ETON) Operating Leases (2019 - 2025)

Eton Pharmaceuticals has disclosed Operating Leases across 7 years of filings, most recently posting $460000.0 for Q4 2025.

• Operating Leases for Q4 2025 came in at $460000.0, up 329.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $460000.0 (up 329.91% YoY), and the FY2025 annual result was $460000.0, up 329.91% from the prior year.
• Operating Leases came in at $460000.0 for Q4 2025 at Eton Pharmaceuticals, down from $480000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $492000.0 in Q2 2025 to a low of $15000.0 in Q4 2021.
• The 5-year median for Operating Leases is $79000.0 (2021), against an average of $135947.4.
• Across the five-year window, Operating Leases slumped 84.85% in 2021 and jumped 613.33% in 2022, its largest moves.
• Eton Pharmaceuticals' Operating Leases stood at $15000.0 in 2021, then surged by 613.33% to $107000.0 in 2022, then plunged by 79.44% to $22000.0 in 2023, then soared by 386.36% to $107000.0 in 2024, then surged by 329.91% to $460000.0 in 2025.
• The last three Operating Leases figures came in at $460000.0 (Q4 2025), $480000.0 (Q3 2025), and $492000.0 (Q2 2025), per Business Quant data.